NDC 0173-0898
Jemperli
Dostarlimab
Jemperli is a Intravenous Injection in the Human Prescription Drug category. It is labeled and distributed by Glaxosmithkline Llc. The primary component is Dostarlimab.
| Product ID | 0173-0898_36d1f683-5a6d-4751-82fd-25f03c3c304f |
| NDC | 0173-0898 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Jemperli |
| Generic Name | Dostarlimab |
| Dosage Form | Injection |
| Route of Administration | INTRAVENOUS |
| Marketing Start Date | 2021-04-22 |
| Marketing Category | BLA / |
| Application Number | BLA761174 |
| Labeler Name | GlaxoSmithKline LLC |
| Substance Name | DOSTARLIMAB |
| Active Ingredient Strength | 50 mg/mL |
| NDC Exclude Flag | N |
| Listing Certified Through | 2022-12-31 |
Packaging
NDC 0173-0898-03
1 VIAL in 1 CARTON (0173-0898-03) > 10 mL in 1 VIAL
| Marketing Start Date | 2021-04-22 |
| NDC Exclude Flag | N |
| Sample Package? | N |
Drug Details
Trademark Results [Jemperli]
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 JEMPERLI 88587355 not registered Live/Pending |
Tesaro, Inc. 2019-08-21 |
© 2025 FDA.report
This site is not affiliated with or endorsed by the FDA.